Skip to main content

Day: August 1, 2024

Endeavour Silver Announces Q2 2024 Financial Results; Earnings Call at 10AM PDT (1PM EDT) Today

VANCOUVER, British Columbia, Aug. 01, 2024 (GLOBE NEWSWIRE) — Endeavour Silver Corp. (“Endeavour” or the “Company”) (NYSE: EXK; TSX: EDR) announces its financial and operating results for the three and six months ended June 30, 2024. All dollar amounts are in US dollars (US$). “During Q2 2024, the construction of the Terronera project continued to make excellent progress, with significant advance of the upper plant platform surface infrastructure. Staying on track for Q4 2024 commissioning reflects our team’s planning, execution and dedication while ensuring financial stability and operational momentum. We are in our last big push before the finish line and remain focused on delivering value to our stakeholders,” stated Dan Dickson, CEO of Endeavour Silver. Q2 2024 HighlightsProduction Tracking Towards Upper Range of Guidance:...

Continue reading

Brookfield Infrastructure Reports Second Quarter 2024 Results

BROOKFIELD, News, Aug. 01, 2024 (GLOBE NEWSWIRE) — Brookfield Infrastructure Partners L.P. (Brookfield Infrastructure, BIP, or the Partnership) (NYSE: BIP; TSX: BIP.UN) today announced its results for the second quarter ended June 30, 2024. “We delivered strong second-quarter results driven by robust organic growth and the positive impact of several years of outsized capital deployment,” said Sam Pollock, Chief Executive Officer of Brookfield Infrastructure Partners. “The outlook for growth is very favorable as the surge in AI adoption is generating substantial capital deployment opportunities across our data, electric utility and natural gas sectors.”  For the three monthsended June 30   For the six monthsended June 30US$ millions (except per unit amounts), unaudited1   2024       2023       2024       2023  Net...

Continue reading

Gildan Activewear Reports Results for the Second Quarter of 2024, Reconfirms its Full Year Guidance and Provides Three-Year Outlook

 (all amounts are in U.S. dollars except where otherwise indicated)(1) Please refer to “Definition and reconciliation of non-GAAP financial measures” in this press release Net sales of $862 million Operating margin of 16.4%, adjusted operating margin1 of 22.7% GAAP diluted EPS of $0.35 and adjusted diluted EPS1 of $0.74 Cash flow from operations of $140 million and free cash flow1 of $104 million Capital returned to shareholders of $182 million during the quarter through dividends and share repurchases Company announces a Normal Course Issuer Bid to repurchase up to 10% of the Company’s public float Company reconfirms its full year 2024 guidance and provides three-year outlook Gildan recognized as one of the Best 50 Corporate Citizens in Canada by Corporate Knights and is included in the inaugural edition...

Continue reading

Onity Group Announces Second Quarter 2024 Results

Net income of $11 million and diluted earnings per share of $1.33; annualized return on equity of 10% Adjusted pre-tax income of $32 million, driven by servicing segment 28% annualized adjusted pre-tax return on equity $19 billion in total servicing additions ($12 billion in subservicing additions) Debt-to-equity ratio of 3.88 to 1 Entered into a letter of intent in July for the acquisition of reverse mortgage assets from Waterfall Asset ManagementWEST PALM BEACH, Fla., Aug. 01, 2024 (GLOBE NEWSWIRE) — Onity Group Inc. (NYSE: ONIT) (“Onity” or the “Company”), a leading non-bank mortgage servicer and originator, today announced its second quarter 2024 results and provided a business update. The Company reported GAAP net income of $11 million for the second quarter with an adjusted pre-tax income of $32 million (see “Note Regarding...

Continue reading

Denali Therapeutics Reports Second Quarter 2024 Financial Results and Business Highlights

SOUTH SAN FRANCISCO, Calif., Aug. 01, 2024 (GLOBE NEWSWIRE) — Denali Therapeutics Inc. (Nasdaq: DNLI), a biopharmaceutical company developing a broad portfolio of product candidates engineered to cross the blood-brain barrier (BBB) for the treatment of neurodegenerative diseases and lysosomal storage diseases, today reported financial results for the second quarter ended June 30, 2024, and provided business highlights. “In the second quarter, our Enzyme Transport Vehicle franchise gained additional momentum with continued engagement with the FDA on an accelerated approval pathway for tividenofusp alfa (DNL310, ETV:IDS) in MPS II and the FDA’s selection of DNL126 (ETV:SGSH) in MPS IIIA for the START program,” said Ryan Watts, Ph.D., Chief Executive Officer of Denali Therapeutics. “Today, we are also pleased to...

Continue reading

XPO Reports Second Quarter 2024 Results

GREENWICH, Conn., Aug. 01, 2024 (GLOBE NEWSWIRE) — XPO (NYSE: XPO) today announced its financial results for the second quarter 2024. The company reported diluted earnings from continuing operations per share of $1.25, compared with $0.27 for the same period in 2023, and adjusted diluted earnings from continuing operations per share of $1.12, compared with $0.71 for the same period in 2023.Second Quarter 2024 Summary Results                                 Three months ended June 30,    Revenue   Operating Income (Loss)(in millions)     2024     2023   Change %   2024       2023     Change %North American Less-Than-Truckload Segment   $ 1,272   $ 1,136   12.0 %   $ 203     $ 129     57.4 %European Transportation Segment     808     781   3.5 %     10       12     -16.7 %Corporate     –     –   0.0 %     (16 )     (34 )   -52.9 %Total   $ 2,079   $ 1,917   8.5 %   $ 197     $ 107     84.1 %                                 Three...

Continue reading

Agios Reports Business Highlights and Second Quarter 2024 Financial Results

– Reported Positive Topline Data from Phase 3 ENERGIZE-T Study; Expect to File sNDA Based on ENERGIZE and ENERGIZE-T Studies Encompassing All Thalassemia Subtypes by End of 2024 – – Announced $905 Million Purchase Agreement for Vorasidenib Royalty with Royalty Pharma; Agios to Receive a Total of $1.1 Billion in Payments Upon FDA Approval of Vorasidenib – – Reported Results from Phase 3 ACTIVATE-KidsT Study of Mitapivat in Children with Pyruvate Kinase (PK) Deficiency Who are Regularly Transfused – – PYRUKYND® (Mitapivat) Net Revenue of $8.6 Million in Q2; Cash, Cash Equivalents and Marketable Securities of $645.3 Million as of June 30, 2024 – CAMBRIDGE, Mass., Aug. 01, 2024 (GLOBE NEWSWIRE) — Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a leader in cellular metabolism and pyruvate kinase (PK) activation pioneering therapies for...

Continue reading

Targa Resources Corp. Reports Record Second Quarter 2024 Results and Increases Full Year 2024 Outlook

HOUSTON, Aug. 01, 2024 (GLOBE NEWSWIRE) — Targa Resources Corp. (NYSE: TRGP) (“TRGP,” the “Company” or “Targa”) today reported second quarter 2024 results. Second quarter 2024 net income attributable to Targa Resources Corp. was $298.5 million compared to $329.3 million for the second quarter of 2023. The Company reported adjusted earnings before interest, income taxes, depreciation and amortization, and other non-cash items (“adjusted EBITDA”)(1) of $984.3 million for the second quarter of 2024 compared to $789.1 million for the second quarter of 2023. HighlightsRecord adjusted EBITDA for the second quarter of $984.3 million Record Permian, NGL transportation, and fractionation volumes during the second quarter Repurchased a quarterly record $355.1 million of common stock during the second quarter Announced a new $1.0 billion...

Continue reading

Landsea Homes Reports Second Quarter 2024 Results

Home sales revenue increased 43.5% to $418.2 million Net new home orders of 760 increased 34.5% Net income of $2.9 million or $0.08 per share Adjusted net income of $13.3 million or $0.36 per share, a 9% increase Home sales gross margin of 14.9%, 21.1% on an adjusted basis Book value per share of $17.94DALLAS, Aug. 01, 2024 (GLOBE NEWSWIRE) — Landsea Homes Corporation (Nasdaq: LSEA) (“Landsea Homes” or the “Company”) announced today financial results for the second quarter ended June 30, 2024. For the quarter, the Company reported pretax income of $4.6 million, and net income of $2.9 million, or $0.08 per share. Reported income for the quarter includes a $5.2 million or $0.10 per diluted share impact related to a non-cash deferred financing cost write-off associated with the re-cast of the Company’s unsecured revolving credit...

Continue reading

EXL Reports 2024 Second Quarter Results

2024 Second Quarter Revenue of $448.4 Million, up 10.7% year-over-year Q2 Diluted EPS (GAAP) of $0.28, down 4.1% from $0.29 in Q2 of 2023 Q2 Adjusted Diluted EPS (Non-GAAP) (1) (2) of $0.40, up 10.8% from $0.36 in Q2 of 2023 NEW YORK, Aug. 01, 2024 (GLOBE NEWSWIRE) — ExlService Holdings, Inc. (Nasdaq: EXLS), a leading data analytics and digital operations and solutions company, today announced its financial results for the quarter ended June 30, 2024. Rohit Kapoor, chairman and chief executive officer, said, “We are pleased with our second quarter results. We delivered both revenue and adjusted diluted EPS growth of 11%. The ongoing execution of our data and AI-led strategy enabled us to accelerate our growth rates across both our data analytics and digital operations and solutions businesses during the quarter as we continue our...

Continue reading

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.